Stockreport

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study [Yahoo! Finance]

Quoin Pharmaceuticals, Ltd. - American Depositary Shares  (QNRX) 
PDF Up to eight subjects will have QRX003 applied twice daily to greater than 80% of their body surface area over a 12-week period Study intended to generate data based o [Read more]